Five months after a "breakthrough" HIV prevention drug got approval in the United States and became available in many wealthy countries, it's getting rolled out in two African countries hit especially hard by the disease.

On Wednesday, the U.S. State Department announced that Eswatini and Zambia have each received 500 doses of lenacapavir, a drug manufactured by Gilead Sciences that's been hailed as by Science as a " breakthrough ." Just two injections a year provide near-complete protection against an HIV infection.

"This is somewhat unprecedented, to see an innovation in global health move this fast to low- and middle-income countries," says Mitchell Warren, the executive director of AIDS Vaccine Advocacy Coalition (AVAC), a global HIV prevention organization. "Obviously very sma

See Full Page